GLP-1 therapies have become a key part of todays diabetes treatment algorithm, helping providers balance glucose control, cardiovascular risk, and patient preferences
For a deeper look at outcomes over 48 weeks, see our Retatrutide results
In contrast, the control group comprised patients with obesity who did not receive a GLP-1 prescription during the study timeframe
Ultimately, the success of the GLP-1 Bridge will depend on its ability to balance access, cost, and long-term value
Having said that, we do see that there is a shift to healthier foods, and that certainly will include healthier snacking," Johnson said
Sounds like big risks for very little potential reward Join the conversation